AP01
Phase 2Small molecule
AP01 is one of 11 small molecule programs targeting Pulmonary Fibrosis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Pulmonary Fibrosis
#DrugCompanyPhaseTrials
1Colcrys
Jazz PharmaceuticalsApproved
Remodulin
United TherapeuticsApproved
Pomalyst
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Cytoxan
BBaxter Healthcare Corporation
Approved
Ofev
Boehringer IngelheimPhase 3
BMS-986278
Bristol-Myers SquibbPhase 3
CBP8
MMassachusetts General Hospital
Phase 2
HRS-9813
Guangdong Hengrui Pharmaceutical Co., LtdPhase 2
AP01
AAvalyn Pharma Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AP01. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAvalyn Pharma Inc.